These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15553982)

  • 1. Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury?
    Albensi BC; Igoechi C; Janigro D; Ilkanich E
    Am J Alzheimers Dis Other Demen; 2004; 19(5):269-74. PubMed ID: 15553982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists.
    Muir KW
    Curr Opin Pharmacol; 2006 Feb; 6(1):53-60. PubMed ID: 16359918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing conditions significantly attenuate the neuroprotective efficacy of competitive, but not other NMDA receptor antagonists in vitro.
    Pringle AK; Self J; Eshak M; Iannotti F
    Eur J Neurosci; 2000 Nov; 12(11):3833-42. PubMed ID: 11069578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA; Wenk GL
    CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
    Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
    Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
    Molinuevo JL; Lladó A; Rami L
    Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?
    Ikonomidou C; Turski L
    Lancet Neurol; 2002 Oct; 1(6):383-6. PubMed ID: 12849400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats.
    Rao VL; Dogan A; Todd KG; Bowen KK; Dempsey RJ
    Brain Res; 2001 Aug; 911(1):96-100. PubMed ID: 11489449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine improves outcomes after repetitive traumatic brain injury.
    Mei Z; Qiu J; Alcon S; Hashim J; Rotenberg A; Sun Y; Meehan WP; Mannix R
    Behav Brain Res; 2018 Mar; 340():195-204. PubMed ID: 28412305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro galantamine-memantine co-application: mechanism of beneficial action.
    Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
    Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones.
    Wild AR; Akyol E; Brothwell SL; Kimkool P; Skepper JN; Gibb AJ; Jones S
    Neuropharmacology; 2013 Oct; 73():138-46. PubMed ID: 23727219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease.
    Yu SP; Jiang MQ; Shim SS; Pourkhodadad S; Wei L
    Mol Neurodegener; 2023 Jul; 18(1):43. PubMed ID: 37400870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine: an antiglutamatergic option for dementia.
    Molinuevo JL; Garcia-Gil V; Villar A
    Am J Alzheimers Dis Other Demen; 2004; 19(1):10-8. PubMed ID: 15002339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise and fall of NMDA antagonists for ischemic stroke.
    Hoyte L; Barber PA; Buchan AM; Hill MD
    Curr Mol Med; 2004 Mar; 4(2):131-6. PubMed ID: 15032709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.
    Chen HS; Pellegrini JW; Aggarwal SK; Lei SZ; Warach S; Jensen FE; Lipton SA
    J Neurosci; 1992 Nov; 12(11):4427-36. PubMed ID: 1432103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.